Article

Phase I clinical trial of CD19 CAR-T cells expressing CXCR5 protein for the treatment of relapsed or refractory B-cell lymphoma

2023-01-12

Abstract excerpt

<h4>Background: </h4> The difficulty of CD19 CAR-T cells entering solid tumors is one of the reasons for its poor efficacy in the treatment of lymphoma.The chemokine CXCL13 secreted by stromal cells of the lymph nodes, induces the homing of B and T lymphocytes who express its receptor CXCR5. Pre-clinical trials have shown that CD19 CAR-T cells expressing CXCR5 could increase its migration to the tumor microenviron...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 29741db4-054f-571d-84a0-de6cd1f82eec
DOI: 10.21203/rs.3.rs-2459480/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase I clinical trial of CD19 CAR-T cells expressing CXCR5 protein for the treatment of relapsed or refractory B-cell lymphomaDOI 10.21203/rs.3.rs-2459480/v1Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity Read

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaSemantic proximity Read

Treatment Outcome of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse by Anti-CD19 CAR-TSemantic proximity Read

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Semantic proximity Read

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsSemantic proximity Read

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasSemantic proximity Read

The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemiaSemantic proximity Read

One Patient Diagnosed With Primary Refractory Diffuse Large B Cell Lymphoma Successfully Salvaged With BCL2 Inhibitor Followed by anti-CD19 CAR-T Suffered From a Secondary Onset of Severely CRSSemantic proximity Read